BioArctic AB

BIOA-B.ST · Health Technology · Biotechnology · SE

43 employees · bioarctic.se

About

BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide.

Annual results

Reported figures, SEK · revenue up 677.8% in 2025

YearRevenueNet incomeNet marginFree cash flow
20252.0B1.0B51.1%—
2024257M-177M-68.9%—
2023615M229M37.2%—
2022228M-11.0M-4.8%—
202123.0M-119M-517.4%—

Dividends per share

2026 2.00 SEK2019 1.50 SEK

BIOA-B.ST in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for BioArctic AB are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

BioArctic AB (BIOA-B.ST) — company profile and financials · MarketPulse